Shares in Alnylam Pharmaceuticals jumped after the company said a drug to treat a rare genetic form of heart disease met its goals in a late-stage trial, opening up the possibility of billions of dollars in additional sales for one of the most valuable US biotechs.
Alnylam Pharmaceuticals股价大涨，此前该公司表示，一款治疗罕见遗传性心脏病的药物在后期试验中达到目标，使这家美国市值最高的生物技术公司之一有望增添数十亿美元的销售额。
您已阅读8%（359字），剩余92%（4277字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。